Evolving Treatment Paradigms for Advanced Urothelial Carcinoma

Learning Objectives:

1. Examine recent evolutions in bladder cancer management, including newly-approved indications, recently-reported data, and current consensus guidelines for advanced bladder cancer.
2. Design evidence-supported treatment plans for patients with advanced bladder cancer by incorporating disease-specific (i.e., performance status, renal function, etc.) and patient-specific factors (i.e., PD-L1 expression, FGFR mutation status, etc.) with guideline recommendations.
3. Recognize and manage treatment-related adverse events from immune checkpoint inhibitors, ADCs, and FGFR inhibitors in patients with advanced bladder cancer.